The growth of new blood vessels is an essential condition for the development of tumors with a diameter greater than 1 ± 2 mm and also for their metastatic dissemination. RNasin, the placental ribonuclease inhibitor, is known to have antiangiogenic activity through the inhibition of angiogenin and basic fibroblast growth factor. Nevertheless, the administration of the recombinant form of a protein poses several limitations; as a result, we have studied the antitumor effect of RNasin in a murine gene therapy model. RNasin cDNA was subcloned into the pcDNA3 expression vector, and the resulting recombinant plasmid was used to transfect the B16 murine melanoma cell line. An RNasin inverted construction was used as control. Mice intravenously injected with clones expressing RNasin showed a significant inhibition of tumor metastatic progression with respect to control groups ( P < .001 ) and survived longer ( P < .001 ) . Tissue sections from RNasin -expressing cell tumors showed a lower number of blood vessels when compared to tissue sections from mice lungs that had been inoculated with control cell lines. The results of these experiments show that the genetic modification of tumor cells with RNasin cDNA yields a significant antitumor effect, and suggest that this effect is at least partially the result of angiogenesis inhibition. Cancer Gene Therapy ( 2001 ) 8, 278 ± 284
A ntiangiogenic gene therapy has been shown to be an important and potent procedure for limiting tumor growth and metastasis without significant side effects because neoplastic progression relies on the ability of the tumor to recruit a new vascular supply. 1 This new strategy offers a unique opportunity to design an effective and selective therapy for all types of cancer, while minimizing the risks of inducing drug resistance. 2 Antiangiogenic gene therapy has focused on two main aspects: ( a ) suppressing the expression of, or disrupting, specific signaling pathways of angiogenic factors; 3 ± 5 and ( b) transferring genes encoding antiangiogenic molecules that cause selective apoptosis of endothelial cells. 6 ± 8 In this context, the search for new antiangiogenic agents continues while awaiting the results of ongoing clinical trials involving a number of antiangiogenic drugs.
RNasin is a ribonuclease inhibitor that has been reported to exhibit antiangiogenic activity. 9 RNasin inhibits the strong angiogenic response generated by either basic fibroblast growth factor ( b-FGF ) 9 or angiogenin. 10 In addition, Polakowski et al 9 demonstrated the ability of RNasin to inhibit tumor growth in mice when administering the recombinant molecule systemically. To examine the potential role of RNasin in the gene therapy of cancer, we transfected the murine melanoma cell line B16 with RNasin cDNA, and clones of B16 tumor cells expressing the exogenous gene were isolated to study their in vivo growth characteristics in an experimental lung metastases model. We expected that intratumor RNasin production by genetically modified cells could contribute to limiting tumor growth by decreasing the number of vessels within the tumor. Although it has been demonstrated that the systemic administration of angiogenesis inhibitors, such as angiostatin and endostatin, can mediate tumor regression, 11, 12 a substantial body of evidence points to the importance of a``local balance'' in angiogenesis 13 and of cell ± matrix interactions in tumor progression. 14, 15 Local delivery of RNasin within the tumor should be able to alter the angiogenic balance more effectively, and above all more persistently, than systemic administration of the protein. Our data show that the intravenous ( i.v.) injection of melanoma cells expressing RNasin mRNA leads to a great decrease in the number of intratumor vessels, with a statistically significant reduction in the number of lung metastases, and increased survival among tumor-bearing mice.
MATERIALS AND METHODS

Generation of RNasin constructs
The pGEM plasmid containing human RNasin cDNA was generously provided by Dr. Curiel ( University of Alabama at Birmingham, UT ). A 1.64 -kb EcoRI fragment of pGEM containing the entire RNasin coding sequence was subcloned into the EcoRI site of the pcDNA3 (Invitrogen, Carlsbad, CA ) expression vector. An asymmetric XhoI restriction site within the EcoRI fragment was used to orientate the plasmid. Two plasmids were then constructed: ( a) p3C -RNasin, with the full coding sequence of RNasin cDNA in the sense 5 H ±3 H orientation, allowing the expression of RNasin protein; and ( b) p3C -éRNasin, with the RNasin cDNA in the reverse antisense 3 H ±5 H orientation (which resulted in no protein synthesis and was used as transfection control ) . Plasmids were amplified in DH5 and purified using Qiagen Maxi kit Endofree (Qiagen, Santa Clarita, CA ) .
Cell culture and transfection
B16 cells were incubated at 378C in a humidified 5% CO 2 , 95% O 2 atmosphere in Dulbecco's modified Eagle's medium ( DMEM ) with 3.7 g /L NaHCO 3 supplemented with 100 U / mL penicillin, 100 g/mL streptomycin, and 10% ( vol /vol) serum (fetal bovine serum; Labtech ). Cells were transfected using the cationic lipid DOTAP purchased from Boehringer Mannheim. DOTAP suspension was mixed with the pcDNA3 constructs (3.7 g:1 g) , and the DOTAP ± plasmid complexes were incubated for at least 30 minutes at 378C with shaking.
Clone selection
Individual cell clones were selected for growth in the presence of G418 ( 2.0 mg /mL ). To ensure that the clones presented a stable expression of the gene, cells were seeded at a low dilution (4Â10 3 ) on a plaque, and their growth was closely followed to isolate ( with cloning cylinders and trypsin; Sigma, St. Louis, MO ) only those colonies that could be identified from the beginning as arising from a single individual cell. Total RNA from lungs was purified using TRI -REAGENT ( Sigma ). To assess RNasin expression, 0.2 g was analyzed by one -step RT-PCR (Gibco) and PCR of a dilution 1:10 of the RT-PCR product with Taq Polymerase ( Biotools ) using the following primers: RNasin-F1, 5
RNasin mRNA expression
H -CCAAGCCGGAC-TTCAAGGA -3
H , and RNasin-R1, 5
H , giving rise to a 60 -bp band.
Experimental metastases and survival experiments
To determine whether RNasin could inhibit the growth of tumor metastases, two separate experiments injecting into the tail vein of syngeneic male C57BL /6 mice ( Iffa-Credo, France ) a single cell suspension of 100 L containing 10 4 or 10 5 tumor cells were carried out. Three weeks after injection, the animals were euthanized, the lungs were removed, and the number of metastases counted by two blind observers under a Stereo Zoom microscope (Leica 2000 ). In a separate set of experiments, mice were i.v. inoculated with 10 5 tumor cells and followed until death to evaluate and compare their survivals. Differences in tumor growth between mice inoculated with different cell lines were evaluated by the Mann -Whitney U test (non -normal distribution ) , and survival was analyzed by the Fisher exact test. A P value of under .05 was considered statistically significant.
Cell proliferation assays
To measure the in vitro proliferation of the parental melanoma cell line B16 and of the genetically modified cell lines, cells were plated at a concentration of 5Â10 4 in triplicate wells of six -well plates in DMEM with 10% fetal bovine serum. Three wells were trypsinized and counted with a hemocytometer every 24 hours for 5 days to determine the number of cells per well.
Histological and immunohistochemical examination of lung metastasis
To study the metastatic lung implants, hematoxylin ± eosin ± stained tissue sections from excised lungs of mice that had been injected with 10 4 tumor cells and sacrificed on day 21 were examined. Microvessels were counted under the light microscope in 10 high -power fields (Â40) corresponding to areas with the highest density of vessels. The maximum number of fields was considered in smaller metastases that did not allow the counting of 10 high -power fields. Immunohistochemical studies were performed to confirm the degree of tumor-induced angiogenesis. An antigenretrieving step was undertaken by means of a pressure container kept at 1.5 atm for 3 minutes. Tissue sections were incubated for 60 minutes with monoclonal anti -CD34 antibody (Biogenes, Menarini Diagnostics, Barcelona, Spain ). The rest of the procedure were performed following the specifications of the System LSAB -2 ( Dako ), and finally the slides were incubated in a solution of dimethylaminoazobenzene.
RESULTS
Generation and characterization of RNasin -expressing cell lines
To generate RNasin -expressing murine melanoma cells, the vector p3C -RNasin was transfected into the B16 murine melanoma cell line. As transfection control, the vector p3C-éRNasin, which has the RNasin cDNA inserted in the reverse antisense 3
H ±5 H orientation, was transfected into the parental B16 cell line. Clones were selected as described in Materials and Methods, and the expression of the transfected RNasin cDNA was assessed by reverse PCR in total cellular RNA. Twenty -one days later, the mice were sacrificed, and the lungs harvested, fixed in 10% formalin, and photographed. A considerably larger number of metastases ( forming confluent tumoral masses in some lungs ) can be appreciated in those mice inoculated with control cells ( B16 and B16éRNasin ) than in mice inoculated with RNasinexpressing cells. Three clones, which expressed RNasin RNA (B16RNasin1 ± 3 ), and one clone transfected with the p3C -éRNasin control vector, which did not express RNasin RNA (B16éRNasin) , were selected for in vivo experiments (Fig 1) .
To assess whether the transfection process itself or RNasin expression by the p3CRNasin clones exerted a direct effect on cell growth in vitro, the proliferation rates of the transfected cells were compared with those of the parental melanoma cell line. These studies showed that the in vitro proliferation rates of the RNasin -expressing melanoma cells ( doubling times for clone B16RNasin 1, 2, and 3 were 15.5, 14.9, and 9 hours, respectively ) did not differ significantly from those of the parental B16 cell line ( 12.7 hours ) or the control cell line B16éRNasin ( 12.6 hours ).
Experimental metastases
A first experiment was carried out to evaluate the role of RNasin expression in the development of lung metastases by injecting mice i.v. (n =10 ) with 10 5 tumor cells of the following clones: B16RNasin1 and 2, B16éRNasin, and the parental B16 melanoma cell line. Twenty-one days after injection, two mice had already died, one belonging to the group inoculated with B16 cells, and the other to the group inoculated with B16éRNasin cells. At this point, the remaining animals were sacrificed. Gross examination revealed a considerably higher number of metastases in those mice inoculated with control cell lines (B16éRNasin and B16 ) than in those receiving B16RNasin cells ( Fig 2) . Comparison of tumor metastases by measuring increases in lung weight confirmed that mice injected with control cell lines carried a significantly greater metastatic burden ( B16: 1.022 0.297 g, B16éRNasin: 1.076 0.316 g) than mice injected with RNasin-expressing cells (clone 2: 0.585 0.074 g, clone 3: 0.577 0.189 g ) (P < .001) .
In a separate experiment, mice were injected in the tail vein with 10 4 tumor cells /animal to determine whether RNasin was able to suppress tumor growth more efficiently when a lower number of cells were injected. All animals were sacrificed on day 21 after injection, and lung metastases Table 1 , and stress the conclusion drawn from the previous experiment where we injected each mouse with 10 5 cells, i.e., mice injected with RNasin-expressing cells had a significantly lower number of lung metastases ( mean number of metastases per animal: 5.3, 3.0, and 37 for clones 1, 2, and 3, respectively ) than those injected with B16éRNasin (144.2 metastases ).
Survival
Survival studies were conducted to compare mice inoculated with either RNasin -expressing or non -RNasin ±expressing melanoma cells. Differences in survival between mice injected with RNasin -expressing cells ( clones 1 and 2 ) and non-RNasin ±expressing cells ( B16 ) are shown in Figure 3 . The results of this experiment indicate that whereas 90% and 100% of mice injected with RNasin clones 1 and 2, respectively, were alive on day 26, all mice receiving B16 cells were dead at this point in time (P < .001) .
Histological and immunohistochemical examination of lung metastases and RNasin RT -PCR
To study the metastatic lung implants, hematoxylin ± eosin ± stained tissue sections from excised lungs corresponding to mice inoculated with 10 4 tumor cells and sacrificed on day 21 were examined (Fig 4 ) . Apart from the scarcity of metastases in the lungs of mice injected with RNasinexpressing melanoma cells, it was apparent that Ð when present Ð the metastatic foci were considerably smaller in these animals. Nevertheless, the most notable finding was the rich vascular network discernible in the B16éRNasin lung metastases, whereas vessels were almost absent in the metastatic foci corresponding to B16RNasin cells ( Fig 5A ) . Immunohistochemical staining with an antibody against endothelial cells confirmed the observation regarding the hematoxylin ± eosin ±stained tissue sections. In addition, the RT-PCR confirmed (Fig 5B ) RNasin expression in metastatic lungs from mice injected with genetically modified cells, but not in lungs from mice injected with wild -type B16 melanoma cells.
DISCUSSION
Angiogenesis comprises the formation of new capillaries from the preexisting vascular blood vessels, and is required for a variety of physiological processes such as wound healing, the menstrual cycle, development, and reproduction. 16 Nevertheless, neovascularization is an essential component of several diseases including atherosclerosis, diabetic retinopathy, psoriasis, and tumor growth. 17, 18 Experimental evidence suggests that avascular tumors rarely grow to over 1 mm 3 in size, and lack metastatic potential. 18 Rupture of the delicate balance between tumor angiogenic stimulators and inhibitors in favor of an angiogenic phenotype allows tumors to grow and metastasize. For a tumor to become angiogenic, it must up -regulate the production of angiogenic stimulators while simultaneously down -regulating angiogenic inhibitors. In this sense, vascular endothelial growth factor and fibroblast growth factor are the angiogenic factors most commonly expressed in tumors. 19 ± 21 RNasin is a molecule with demonstrated antiangiogenic properties. Nevertheless, when studying RNasin action, one of the most discouraging obstacles arises from the fact that RNasin activity in serum cannot be detected even 1 hour after the administration of a recombinant form of placental RNasin. 9 However, RNasin-associated antigens can be detected for several days by Western blot analysis, implying that although the molecule or fragment of it persists over the long term following administration, its biological activity is rapidly lost. 9 To circumvent this problem, we designed a gene therapy model transfecting the melanoma cell line B16 with RNasin cDNA, with the aim of obtaining a continuous local source of RNasin. Although the use of tumoral cells already stably transfected is a limited model of gene therapy, it opens a way to new approaches based on tumor treatment with more efficient vectors. Three clones ( B16RNasin1 ± 3) obtained from transfection of B16 cells with p3C -RNasin vector, and in which expression of RNasin RNA was confirmed, were selected for in vivo experiments. Additionally, one clone (B16éRNasin) derived from the transfection of B16 cells with p3C -éRNasin, in which RT-PCR failed to show RNasin RNA expression, was also selected. To study the tumor progression ability of each clone, mice were i.v. injected into the tail vein in separate experiments with 10 4 or 10 5 cells, and both superficial lung metastasis and survival It has been demonstrated that angiogenic inhibition induced by RNasin takes two routes. In the first, RNasin binds to angiogenin with extraordinary affinity, abolishing both its enzymatic and biological properties. 10, 19 Angiogenin is a potent blood vessel ± inducing 15 -kDa polypeptide 20 whose primary structure is highly homologous to that of the pancreatic ribonucleases. 21, 22 Numerous studies have provided evidence that the ribonucleolytic action of angiogenin is a requirement for its biological proangiogenic activity, 23 ± 26 and that RNasin binding inhibits both the enzymatic and biological activities of angiogenin. 10 If the effects of RNasin are mediated through its binding to angiogenin, RNasin gene therapy should not necessarily lead to a decrease in the amount of secreted angiogenin. Nevertheless, it would be interesting to explore this point in the future. According to the second route, RNasin inhibits the strong angiogenic response induced by b -FGF Ð a potent mitogen and chemotactic factor for endothelial cells. 9 The relationship between angiogenin and b-FGF has not been clarified, though it is likely that more than one angiogenic pathway exists, and that the two molecules are unrelated.
A histological and immunohistochemical study was conducted to assess the differences in vascularization between tumors derived from RNasin-expressing and non -RNasin± expressing clones, as confirmed by RT-PCR from lungs. Whereas no difference in microvessel density was observed in tumors derived from B16 cells or B16éRNasin clone, a more than 10 -fold reduction was observed in tumors derived from clones genetically modified to produce RNasin versus those that do not express it. Thus, our results correlate decreased microvessel density in histological sections to smaller tumor size. However, we cannot affirm whether decreased microvessel density is the primary cause of the smaller tumor size in mice injected with RNasin -expressing cells because it could also be secondary to other mechanisms through which RNasin might inhibit tumor growth. Nevertheless, considering the existing data on RNasin action, the antiangiogenic RNasin effect is the most likely explanation.
Antiangiogenic gene therapy with RNasin depends on the blocking of tumor-derived molecules with proangiogenic activities. This type of antiangiogenic gene therapeutic approach has the disadvantage of an increased risk of inducing drug resistance due to the potential appearance of tumor cells that release a different angiogenic factor. Although RNasin exerts its effect on angiogenesis indirectly through the inhibition of angiogenin and b -FGF, it has the advantage of acting upon two different points in the angiogenic pathway, and is thus less likely to induce resistance. Two areas of future research with RNasin should be considered: the development of adenoviral vectors to evaluate the therapeutic efficacy in an in vivo model, and the modification of RNasin gene to obtain smaller, more stable, and more specific inhibitors of angiogenin. 19 Of special interest are the studies performed by site -specific mutagenesis to identify those residues significant for ribonuclease and angiogenic activity of the molecule. In most instances, the efficacy of angiogenin in performing both activities is correlated, although Hallahan et al 27 have suggested that the RNase active site in angiogenin is essential, but not sufficient, for its angiogenic activity, and that an additional second site on the molecule is required.
